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Paeoniﬂorin (PF) is the main active ingredients of radix paeoniae rubra and radix paeoniae alba, which
are used widely in Traditional Chinese Medicine. This study aimed to assess the capacity of PF to inhibit
imiquimod (IMQ)-induced psoriasis. Mice treated with IMQ were divided into four groups and ad-
ministered 240 mg/kg/day or 120 mg/kg/day of PF, 1 mg/kg/day of methotrexate (MTX), or normal saline
intragastrically. Weight-matched mice treated with vaseline were used as controls. Morphology, struc-
tural features, keratinocyte proliferation and differentiation, inﬂammatory cell inﬁltration, levels of Th1/
Th2/Th17/Treg cytokine mRNA, and phosphorylation of Th17 differentiation-related proteins were as-
sessed. Mouse spleen cells were incubated under Th17 polarizing conditions, then with PF (2, 20, and
200 μg/ml) and cell viability, Th17 differentiation, and Th17 cytokines and the orphan nuclear receptor
(RORγt) mRNA levels were assessed. PF alleviated IMQ-induced keratinocyte proliferation and in-
ﬂammatory cell inﬁltration, and reduced mRNA levels of Th17 cytokines at day 4 and phosphorylation of
Th17 differentiation-related proteins. However, 2, 20, or 200 μg/ml PF did not affect spleen cell viability,
and 2 and 20 μg/ml PF reduced IL-17 secretion under Th17 polarizing conditions. Finally, 2 and 20 μg/ml
PF inhibited mRNA expression of Th17 cytokines and phosphorylation of Stat3 in spleen cells under Th17
polarizing conditions. These results suggest that PF inhibits IMQ-induced psoriasis by regulating Th17
cell response and cytokine secretion via phosphorylation of Stat3.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psoriasis, a T-cell-mediated inﬂammatory skin disease, is
characterized by hyper-proliferation and poor differentiation of
epidermal keratinocytes. It is considered an immunological dis-
ease and is associated with increased vascularization of the skin,
ﬁbroblast activation and leucocyte inﬁltration, but the precise
cellular and molecular mechanisms responsible for this condition
have not been entirely elucidated.
Imiquimod (IMQ) is a ligand of toll-like receptor (TLR) 7 and
8 and a potent immune activator. IMQ is used in the topical
treatment of genital and perianal warts caused by the human
papilloma virus (Beutner and Tyring, 1997) and actinic keratoses
and superﬁcial basal cell carcinomas (Fanti et al., 2006; GillietB.V. This is an open access article u
nic and Basic Research with
stitute of Traditional Chineseet al., 2004; Rajan and Langtry, 2006; Wu et al., 2004). However,
IMQ can exacerbate psoriasis not only at the site of administration,
but also at distant sites, suggesting a systemic response (Fanti
et al., 2006; Rajan and Langtry, 2006; Wu et al., 2004). Application
of IMQ to the skin of mice causes an inﬂux of immune cells, acti-
vation of dendritic cells, inﬂammatory cytokine secretion, and
hyperplasia of the epidermis (Palamara et al., 2004; Gilliet et al.,
2004). These effects are manifested as symptoms of dermatitis
that closely resemble human psoriasis, and this process is reported
to be dependent on the IL-23/IL-17 axis (van der Fits et al., 2009).
As IL-17 is reported to play an important role in psoriasis (re-
viewed in Durham et al. (2015)), IMQ-induced skin inﬂammation
in mice represents a useful model of human psoriasis.
Paeoniﬂorin (PF) is a monoterpene glucoside extracted from
the root of Paeonia lactiﬂora Pall and is the main active ingredients
of radix paeoniae rubra and radix paeoniae alba, which are widely
used in Traditional Chinese Medicine. As an anti-inﬂammatory and
immune-regulatory drug, PF is reported to be effective in the
treatment of several inﬂammatory diseases, including rheumatoidnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2009; Zheng et al., 2007b). Comparison with glucocorticosteroids,
a multi-center clinical trial showed that PF achieved superior
treatment of inﬂammatory diseases, in part due to causing fewer
side effects (Min et al., 2005). Zhang et al. (2012) reported the
therapeutic effect of PF on psoriasis clinically.
Numerous studies have reported that T helper 17 (Th17) cells
and their inﬂammatory mediators, interleukin (IL)-17, IL-22 and IL-
23, are present in psoriatic skin lesions and serum samples taken
from patients with psoriasis, and play a role in the pathogenesis of
psoriasis (Qin et al., 2014). Recently, Sun et al. (2015) reported that
PF alleviates psoriatic skin lesions by reducing the number of
dermal macrophages and neutrophils, and reducing Th1/Th17-as-
sociated cytokine production. However, the mechanism by which
PF regulates Th17 response and cytokine secretion in a mouse
model of IMQ-induced psoriasis are still poorly understood. In this
study, we demonstrated that PF substantially ameliorates IMQ-
induced skin lesions, possibly through inhibiting Th17-mediated
inﬂammatory responses via a Stat3-dependent mechanism.2. Material and methods
2.1. Animals
BALB/c and C57BL/6 mice (18–20 g) were purchased from
Beijing Huafukang Biological Technology Co., Ltd., and housed
under speciﬁc pathogen-free conditions, with access to food and
water ad libitum. All experiments were approved by the institu-
tional animal ethics committee according to the regulations for
animal experiments of the Beijing Institute of Traditional Chinese
Medicine. Mice were anesthetized with sodium pentobarbital
(80 mg/kg) and treated topically with a 42 mg daily dose of
commercially available IMQ cream (5%) (Mingxin Pharmaceuticals,
Sichuan) on the shaved back for 8 consecutive days.
2.2. Grouping and treatment
Mouse models were randomized to four groups: (1) high-dose
PF (purityZ96%, bought from the National Institutes for Food and
Drug Control, Beijing) group (PF High, n¼10), with animals re-
ceiving intragastric administration of PF dissolved in normal saline
at a dose of 240 mg/kg/day for 8 days; (2) low-dose PF group (PF
Low, n¼10), PF at 120 mg/kg/day for 8 days; (3) model group
(model, n¼10), normal saline of the same volume as in PF-treat-
ment groups for 8 days; (4) methotrexate (Shanghai Pharmaceu-
tical Co., Ltd. Shanghai) group (MTX, n¼10), with animals receiv-
ing methotrexate dissolved in normal saline at 1 mg/kg/day for
8 days. Weight-matched mice intragastrically treated with vase-
line (Lanlianfeitian Petrochemical Co., Ltd. Hebei) and normal
saline were used as controls (Control, n¼10). The doses of PF used
in this study, 120 to 240 mg/kg/day, are within the range used in
previous studies (Lin et al., 2012; Zhou et al., 2012). We in-
vestigated the effect of these doses on mouse liver and kidney
function, and no adverse effect was found.
2.3. Scoring of skin inﬂammation severity
To score the severity of back skin inﬂammation, an objective
scoring system was developed based on the clinical Psoriasis Area
and Severity Index (PASI), although the affected skin area was not
taken into account in the overall score. Erythema, scaling, and
thickening were scored independently on a scale from 0 to 4: 0,
none; 1, slight; 2, moderate; 3, marked; 4, very marked. The score
for each group was averaged, and trend lines were generated to
observe the changes in mouse skin lesions.2.4. Sample preparation
According to the nine grid method, tissue lesions were excised
and divided into three parts: a fraction of each tissue was ﬁxed in
10% formalin solution to be parafﬁn embedded, another fraction
was snap frozen to prepare frozen sections, and the ﬁnal portion
was stored at 80 °C for future use.
2.5. Histology
Tissue slices (5 μm) were cut from the parafﬁn sections and
stained with H&E for pathological observation by light microscopy.
Epidermal thickness was accurately measured by the ImagePro
Plus software (Leeds Precision Instruments, Minneapolis, MN,
USA).
2.6. Immunohistochemistry
Parafﬁn-embedded sections were dewaxed for 1 h with xylene
and placed into a sodium citrate solution for 10 min at 95 °C in a
water bath for antigen retrieval. Then, sections were ﬁxed in 3%
H2O2 for 10 min at room temperature, and the slides were in-
cubated overnight at 4 °C with primary antibodies against CD3
(1:200, Abcam, USA), PCNA (1:800, Abcam, USA), and involucrin
(1:200, Abcam, USA). This was followed by incubation for 30 min
with secondary antibodies. DAPI (Sigma, USA) was used for
counterstaining, and DAB (Zhongshan Golden Bridge Biotechnol-
ogy Co., Ltd. China) was used for color development.
Frozen sections were ﬁxed in 3% H2O2 for 10 min at room
temperature. Slides were incubated overnight at 4 °C with primary
antibodies against Gr-1 (1:200, Abcam, USA), followed by in-
cubation for 30 min with secondary antibodies. NovaRED (Vector
Laboratories, USA) was used for color development.
Slides were observed with Olympus DP20 (Japan) and semi-
quantiﬁcation of the staining was performed independently by
two researchers using IPP6.0. Each index was presented as in-
tegrated optical density (IOD).
2.7. Western blotting
Total protein samples from lesion tissues were obtained using a
lysis buffer followed by centrifugation at 4 °C for 5 min at 20,000g.
The concentrations of proteins in supernatants were measured
using a BCA protein assay kit. Proteins from each sample (50 μg)
were resolved on 10% SDS-PAGE gels and transferred onto PVDF
membranes. After blocking with 3% BSA for 30 min at room tem-
perature, membranes were incubated with primary antibodies
against GAPDH (1:10,000, SainuoBo biotechnology, China); P-Stat3
(tyr) (1:1000, Cell Signaling technology, USA); P-Stat3 (ser)
(1:1000, Cell Signaling technology, USA); Stat3 (1:4000, Cell Sig-
naling technology, USA); P-Tyk2 (1:1000, Sigma, USA); Tyk2
(1:500, Abcam, USA); Jak2 (1:1000, Cell Signaling technology,
USA); P-Jak2 (1:1000, Cell Signaling technology, USA) at 4 °C
overnight. The membranes were then washed ﬁve times with
TBST. After incubation with HRP-conjugated secondary antibodies
for 40 min at room temperature, membranes were washed as
described above. Protein bands were visualized with a chemilu-
minescent substrate for HRP and captured on X-ray ﬁlms. Finally,
the ﬁlms were scanned and bands quantiﬁed using the Quantity
one analysis software.
2.8. Th17 cell culture and grouping
Spleen samples from C57BL/6 mice (18–20 g, Beijing Huafukang
Biological Technology Co., Ltd.) were minced on a 200-mm mesh
gauze to obtain single-cell suspensions. Naive CD4þ T-cell sorting
Table 1
Primers for quantitative real-time PCR.
IL-23 Forward 5′-GACTCAGCCAACTCCTCCAGCCAG-3′
Reverse 5′-TTGGCACTAAGGGCTCAGTCAGA-3′
IL-17A Forward 5′-CAGACTACCTCAACCGTTCCA-3′
Reverse 5′-ACAATCGAGGCCACGCAGGTGCAGC-3′
IL-17F Forward 5′-TGCTACTGTTGATGTTGGGAC-3′
Reverse 5′-AATGCCCTGGTTTTGGTTGAA-3′
IL-22 Forward 5′-CGTCAACCGCACCTTTAT-3′
Reverse 5′-AGGGCTGGAACCTGTCTG-3′
TNF-α Forward 5′-GAGAAGTTCCCAAATGGC-3′
Reverse 5′-ACTTGGTGGTTTGCTACG-3′
IFN-γ Forward 5′-TAACTCAAGTGGCATAGATGTGGAAG-3′
Reverse 5′-GACGCTTATGTTGTTGCTGATGG-3′
IL-10 Forward 5′-CTGGACAACATACTGCTAACCGACTC-3′
Reverse 5′-AACTGGATCATTTCCGATAAGGC-3′
K14 Forward 5′-ACGCCCACCTTTCATCTTCCCAAT-3′
Reverse 5′-ATCTGGCGGTTGGTGGAGGTCA-3′
IL-4 Forward 5′-TCGTCTGTAGGGCTTCCAAGGTGCT-3′
Reverse 5′-GTGGACTTGGACTCATTCATGGTGC-3′
β-actin Forward 5′-GCCTTCCTTCTTGGGTAT-3′
Reverse 5′-GGCATAGAGGTCTTTACGG-3′
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Cell Isolated Kit II (Miltenyi biotech, German). After two washes,
2106 cells were seeded in 12-well plates, coated with anti-CD3
(5 μg/ml, eBioscience, USA) and anti-CD28 (2 μg/ml, eBioscience,
USA). Cells were cultured in RPMI-1640 (Hyclone, USA) supple-
mented with 10% FBS (Hyclone, USA), TGF-β1 (5 ng/ml, Peprotech,
USA), IL-6 (20 ng/ml, Peprotech, USA), IL-1β (10 ng/ml, Peprotech,
USA), anti-IL-2 (10 μg/ml, eBioscience, USA), anti-IL-4 (10 μg/ml,
eBioscience, USA), anti-IFN-γ (10 μg/ml, eBioscience, USA), and IL-
23 (15 ng/ml, eBioscience, USA) for three days. Th17 cell differ-
entiation rate was measured by ﬂow cytometry.
CD4þ CD62Lþ T cells were divided into ﬁve group: (1) neutral
conditions, with cells only cultured in wells coated with anti-CD3
(5 μg/ml) and anti-CD28 (2 μg/ml); (2) Th17 polarizing conditions,
where cells were cultured in RPMI-1640 medium containing 10%
FBS and TGF-β1 (5 ng/ml), IL-6 (20 ng/ml), IL-1β (10 ng/ml), anti-
IL-2 (10 μg/ml), anti-IL-4 (10 μg/ml), anti-IFN-γ (10 μg/ml), and IL-
23 (15 ng/ml) for three days to induce Th17 cell differentiation;
(3) high-dose PF (200 mg/ml), with Th17 cell differentiation and
200 mg/ml PF; (4) middle-dose PF (20 mg/ml), Th17 cell differ-
entiation and 20 mg/ml PF; (5) low-dose PF (2 mg/ml), Th17 cell
differentiation and 2 mg/ml PF.
2.9. Flow cytometry
Inguinal lymph nodes samples from each group were minced
through a 70-mm mesh to obtain single cell suspensions. For ﬂow
cytometry analysis, 1106 cells were stained with ﬂuorescein
isothiocyanate (FITC)-conjugated mouse monoclonal anti-γδTCR
(eBiosciences, USA) and allophycocyanin (APC)-conjugated anti-
CD3 (eBiosciences, USA). Samples were analyzed on a ﬂow cyto-
meter (FACScanto; BD Biosciences, San Jose, CA, USA) using Cell-
Quest software (BD Biosciences).
After three days of culture, PMA (10 ng/ml, Sigma, USA), iono-
mycin (1 μg/ml, Sigma, USA), and BfA (10 μg/ml, eBioscience, USA)
were added to the culture at 37 °C and 5% CO2 for 6 h. Cells were
washed twice and stained for 10 min at room temperature with
ﬂuorescence-labeled mAbs diluted in PBS/0.2% BSA (Amresco,
USA), including FITC-conjugated anti-CD4 (eBioscience, USA) and
PE-conjugated anti-IL17 (eBioscience, USA). Data were acquired on
a ﬂow cytometer (FACScan or FACSCalibur; BD Biosciences) and
analyzed using the CellQuest software (BD Biosciences).
2.10. Assessment of cell viability by CCK-8
The effect of PF on cell viability was assessed using the CCK-8
kit (Dojindo Laboratories, Japan): 10 μl of CCK-8 reagent was ad-
ded to each well after 3 days of culture at 37 °C and incubated for
4 h. Then, absorbance was measured on a microplate reader at
450 nm.2.11. Real-time quantitative PCR
Total mRNA was extracted from isolated spleen cells and back
skin samples collected after euthanasia using an ultrapure RNA
extraction kit (Kang Biotechnology Co., Ltd., China). RNA quality
was evaluated by loading 5 μl of sample on 1% agarose gel. Reverse
transcription was carried out with the HiFi-MMLV cDNA ﬁrst
strand synthesis kit (Kang Biotechnology Co., Ltd., China), and PCR
ampliﬁcation done with a ﬂuorescent dye UltraSYBR Mixture
chimeric ﬂuorescence (Kang Biotechnology Co., Ltd., China). The
2△△CT method was used to quantitatively analyze the data. PCR
primers are shown in Table 1.2.12. IL-17 ELISA
The levels of IL-17 in the culture medium were determined
using commercial enzyme linked immunosorbent assay (ELISA)
kits (BMS6001, Bender MedSystems, Austria) with standard curves
made from puriﬁed recombinant IL-17 at various dilutions.
2.13. Statistical analysis
Data are expressed as mean7S.D., and SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis. Student's t-test
was used to compare two groups and ANOVA followed by post-hoc
LSD was used to compare three and more groups. Po0.05 was
considered statistically signiﬁcant.3. Results
3.1. PF improves the morphological features of IMQ-induced psor-
iasis in mice
Compared with normal control mice, the skin of the model
group mice exhibited erythema after treatment with IMQ for
1 day; scaling and thickening of the skin were observed after 2–3
days, with the most serious symptoms (psoriasis-like lesions) ap-
pearing after 7–8 days. During the same period, mice treated with
PF and MTX exhibited decreased erythema, scarce scaly features,
smooth skin, and reduced thickening, and overall skin lesions were
signiﬁcantly reduced (Fig. 1A). Neither PF nor MTX administration
altered the liver and kidney function of the mice. The average PASI
Fig. 1. PF improves the morphological features of IMQ-induced psoriasis in mice. A, Phenotypical presentation of back skin of mice after 2, 4, and 8 days of imiquimod
treatment with the indicated compounds. B, Erythema, scaling, and thickness of the back skin was scored daily on a scale from 0 to 4. The cumulative score (er-
ythemaþscalingþthickness) is depicted. Symbols indicate the mean7S.D. (n¼5).
J. Zhao et al. / European Journal of Pharmacology 772 (2016) 131–143134score of each group was plotted, and the PASI scores within the
subcategories of erythema, scaling, and thickening (Fig. 1B). Nor-
mal control mice exhibited no signiﬁcant changes in PASI scores.
Lesions gradually increased with extended IMQ administration in
the model group. Interestingly, mice treated with PF (high and lowdoses) and MTX exhibited lower PASI scores than the untreated
group. The erythema and scaling scores of the PF high-dose group
roughly overlapped with that of the MTX group. The thickening
and cumulative scores of the PF high-dose group were sig-
niﬁcantly lower than those of the MTX group.
Fig. 2. PF alters keratinocyte proliferation and differentiation. A, Histological changes in mice skin lesions on days 4 and 8 of imiquimod treatment with the indicated
compounds, HE staining of back skin of mice (200 ) (n¼5). B, Effect of PF on PCNA and involucrin expression in lesions on day 8 (n¼4). C, Effect of PF on the expression of
K14 mRNA in lesions on days 4 and 8 of treatment. D, Effect of PF on the expression of RORγt mRNA in lesions after 4 and 8 days of treatment. Data represent the mean7S.D.
(n¼4). *Po0.05, **Po0.01 as indicated.
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mice
HE staining showed thickened prickle cell layer of the epi-
dermis, an increased number of prickle cells, parakeratosis, andresidual condensation of nuclei in the stratum corneum. Munro
micro abscesses were formed, lymphocyte inﬁltration in the der-
mal layer was observed. Similar to the MTX group, PF (high- and
low-dose) treated animals exhibited smoother epidermis, less
parakeratosis, and less epidermal thickening than the model group
Table 2
Epidermis thickness changes of skin lesions in mice (μm, mean7S.D., n¼5).
Time
Group CTRL Model PF high PF low MTX
Day 4 8.6372.01a 70.98715.21 29.1379.94a 49.3375.89a 34.94711.03b
Day 8 9.0672.75a 89.04710.65 41.5877.11a 62.29712.37b 50.72713.19b
CTRL, control; PF, paeoniﬂorin; MTX, methotrexate.
a Po0.01 vs. Model.
b Po0.05 vs. Model.
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ness in the model group was about 8 to 10 times greater than in
the normal control group. Interestingly, epidermal thickening in
the PF and MTX groups was signiﬁcantly reduced (Po0.01 or
Po0.05), and the inhibition of epidermal thickening was greater
in animals that received high-dose PF (Table 2).
3.3. PF alleviates proliferation and differentiation of keratinocytes
PCNA is mainly expressed in the nucleus. Im-
munohistochemistry revealed positive cells with brown particles
within the nucleus. Only the basal layer cells of normal mouse skin
proliferated signiﬁcantly, with PCNA exhibiting a linear arrange-
ment; the number of cells and layers in the colored epidermis
signiﬁcantly increased in the model group. In comparison to the
model group, fewer layers of stained cells were observed in PF
(high and low doses) and MTX groups, with the PF high-dose
having the greatest effect (Fig. 2B). Image analysis revealed a sig-
niﬁcant difference in PCNA levels between the PF high-dose, PF
low-dose, MTX, and model groups (Po0.01) (Table 3).
Involucrin is a keratinocyte differentiation marker. It was
mainly expressed in the cytoplasm, as revealed by immuno-
ﬂuorescence. Involucrin was distributed throughout the stratum
corneum and upper spinous layer of normal mouse skin. In the
model group, it was widely distributed throughout the epidermis,
and high levels of expression indicated abnormal keratinocyte
differentiation. In animals administered PF (high- and low-doses)
and MTX, the distribution of involucrin was normal, and higher
levels were observed in the upper layers of the stratum corneum.
Expression of involucrin was lower in the spine (Fig. 2B) (Table 3).
K14 is a key protein involved in the regulation of keratinocyte
proliferation and differentiation. Quantitative PCR revealed that
compared with normal mouse skin, the level of K14 mRNA ex-
pression was signiﬁcantly higher in model animal lesions 4 and
8 days after administration of IMQ (Po0.01). Interestingly, high-
dose PF signiﬁcantly inhibited K14 mRNA expression (Po0.05).
MTX inhibited K14 mRNA expression only on day 4 (Po0.05). K14
mRNA levels in the MTX group on day 8 did not differ signiﬁcantly
from those of model group animals (P40.05) (Fig. 2C). The orphan
nuclear receptor γt (RORγt) mRNA was elevated in the model
group compared with the three other groups after 4 days of IMQ
treatment (all Po0.05) (Fig. 2D), while there was no differenceTable 3
Effect of paeoniﬂorin on the expression of PCNA and Involucrin in mice with psoriasis-
Target
Group CTRL Model
PCNA 5.5371.93a 18.9875.52
Involucrin 29.3478.79a 652.517117.36
CTRL, control; PF, paeoniﬂorin; MTX, methotrexate. Po0.05 vs. Model.
a Po0.01, vs. Model.between the control, PF, and MTX groups. RORγt mRNA was si-
milar among the four groups after 8 days of IMQ treatment.
3.4. PF alleviates inﬂammatory cell inﬁltration in the psoriasis-like
lesions
CD3 is mainly expressed in T lymphocytes, and appears as
brown particles after immunohistochemistry with the DAB chro-
mogenic agent. Signiﬁcantly more brown particles were observed
in model mice than control mice, indicating signiﬁcantly increased
CD3 expression. Interestingly, CD3 expression in the PF high-dose
group was signiﬁcantly lower than that of the untreated group, but
CD3 expression did not differ signiﬁcantly between PF and MTX
groups (Fig. 3A).
The Gr-1 antibody recognizes neutrophils and monocytes, and
immunohistochemistry with NovaRED can reﬂect the neutrophil
and monocyte content of tissues. Compared with the normal
control group, Gr-1 expression was signiﬁcantly increased in the
model group, while Gr-1 expression in PF (high-dose) and MTX
groups was signiﬁcantly reduced, in comparison to the model
group (Fig. 3B). Image analysis revealed that Gr-1 expression levels
in the PF (high-dose) and MTX group differed signiﬁcantly from
the model group (Po0.01) (Table 4).
3.5. Effect of PF on Th1/Th2/Th17/Treg cytokine mRNA expression in
psoriasis-like lesions of mice induced by IMQ
As illustrated in Fig. 4, the levels of IL-23, IFN-γ, IL-17A, IL-17F,
IL-22, TNF-α, IL-4, and IL-10 mRNA in the skin lesions of IMQ-
treated mice were signiﬁcantly higher than in untreated mice
(control group) on day 4 (Po0.01 or Po0.05). The levels of these
cytokines in the skin lesions of IMQ-treated mice were decreased
on day 8, and the levels of IL-17A, IL-17F, TNF-α and IL-23 mRNA
did not signiﬁcantly differ from the levels in control animals at this
time point (P40.05), while the levels of IL-22, IFN-γ, IL-4, and IL-
10 mRNA remained elevated.
In animals administered high-dose PF, the levels of Th17 cyto-
kine (IL-17A, IL-17F, IL-22, and TNF-α) mRNA were signiﬁcantly
lower than in model animals at day 4 (Po0.01 or Po0.05), in-
dicating that PF inhibited Th17 cytokine expression. On day 8,
mRNA levels of IL-17A and TNF-α subsided in the model group,
and did not differ signiﬁcantly between the PF and model groupslike lesions induced by IMQ (IOD, mean7S.D., n¼4).
PF high PF low MTX
7.7373.16a 10.3374.35a 6.9472.03a
204.30750.27a 378.357101.9a 320.11783.87a
Fig. 3. PF alleviates inﬂammatory cell inﬁltration in psoriasis-like lesions. A, CD3 expression on day 8 (n¼4). B, Gr-1 expression on day 8 (n¼4).
Table 4
Effect of paeoniﬂorin on the expression of CD3 and Gr-1 in mice with psoriasis-like
lesions induced by IMQ (IOD, mean7S.D., n¼4).
Target
Group CTRL Model PF high MTX
CD3 3.3770.68a 11.4972.14 5.0471.05a 5.8870.99a
Gr-1 2.8470.55a 23.2874.56 3.8570.93a 4.2671.32a
CTRL, control; PF, paeoniﬂorin; MTX, methotrexate. Po0.05 vs. Model.
a Po0.01 vs. Model.
J. Zhao et al. / European Journal of Pharmacology 772 (2016) 131–143 137(P40.05). However, IL-22 mRNA levels remained signiﬁcantly
lower in animals administered high dose PF compared with the
model group (Po0.05).
On neither day 4 nor 8 did the mRNA levels of IL-23, Th1 type
cytokine (IFN-γ), Th2 cytokine (IL-4), and Treg cytokine (IL-10)
differ signiﬁcantly between the PF (high-dose) and model groups
(P40.05).
In animals administered MTX, the levels of Th17 cytokine (IL-
17A, IL-17F, and IL-22) mRNA were signiﬁcantly lower than in
model animals on day 4 (Po0.01 or Po0.05), and levels of IL-22
and IFN-γ mRNA were signiﬁcantly lower in the MTX group than
in model animals on day 8 (Po0.01 or Po0.05). However, the
mRNA levels of the remaining cytokines did not differ signiﬁcantly
from the model group (P40.05) (Fig. 4).3.6. Effect of PF on the phosphorylation of Th17 differentiation re-
lated proteins in vivo
The quantity of phosphorylated Stat3 and Tyk2 present in
mouse skin lesions was assessed on day 4 by western blot. Com-
pared with normal control mice, the p-Stat3 (tyr), p-Stat3 (ser),
and p-Tyk2 content of model group lesions were signiﬁcantly in-
creased (Po0.01). The level of p-Stat3 (tyr) in the PF (high-dose)
group was signiﬁcantly reduced (Po0.05), however the level of
p-Tyk2, p-Stat and p-Stat (ser) was not signiﬁcantly altered by PF
administration (P40.05), and the level of p-Tyk2, p-Stat, p-Stat
(tyr), and p-Stat (ser) was not signiﬁcantly altered by MTX ad-
ministration (P40.05). No p-Jak2 expression was detected in
these experiments (Fig. 5).3.7. PF decreased γδ T cells number in IMQ-treated mouse lymph node
Compared with healthy control animals, the ratio of inguinal
lymph node γδ T cells in the model group was signiﬁcantly higher,
and the ratio of γδ T cells was decreased in PF- and MTX-treated
animals. The inhibitory effect of PF was more substantial than that
of MTX (Fig. S1).
3.8. Th17 cell differentiation
As PF modulates Th17 cytokines in IMQ-induced psoriasis,
whether PF affects Th17 cell differentiation in vitro was in-
vestigated. After cell sorting and culture in neutral and Th17 po-
larizing conditions, the status of cells in each group was observed.
Under neutral conditions, cells grew well in visible aggregates,
forming small clumps and with T cell growth characteristics. The
proportion of Th17 (CD4þ/IL-17þ) cells was 1.4570.73%. Under
Th17 polarizing conditions, T cell numbers increased somewhat,
and the majority of cells aggregated into larger clumps. The pro-
portion of Th17 (CD4þ/IL-17þ) cells was signiﬁcantly increased to
21.4571.92% (Po0.01).
3.9. PF does not affect CD4þ CD62Lþ T cell viability
In the CCK-8 assay, OD values of cultures incubated under Th17
polarizing conditions were signiﬁcantly higher than those ob-
tained in neutral conditions (Po0.05). No statistically signiﬁcant
differences were observed between the PF treatment groups and
cells incubated in Th17 polarizing conditions (P40.05). PF (2–
200 μg/ml) did not alter CD4þ CD62Lþ T cell viability (Table 5).
3.10. PF reduced IL-17 secretion
Under Th17 polarizing conditions, incubation with PF (200, 20
and 2 μg/ml) had no signiﬁcant effect on CD4þ IL-17þ Th17 cell
numbers (P40.05). After incubation with 200, 20, and 2 μg/ml of
PF, Th17 ratios were 21.470.47%, 20.2472.16% and 17.4274.09%,
respectively (Fig. 6A and Table 6). Interestingly, the ﬂuorescence
intensity of IL-17-PE in cells incubated with 2 μg/ml PF was sig-
niﬁcantly lower than control cells (Po0.05), while the ﬂuores-
cence intensity of IL-17-PE in cell incubated with 20 or 200 μg/ml
did not differ signiﬁcantly (P40.05; Fig. 6B). This trend was also
observed in measurement of secreted IL-17 by ELISA. The culture
Fig. 4. Effect of PF on mRNA levels of Th1/Th2/Th17/Treg cytokines. Th1 type cytokine (IFN-γ), Th17 cytokines (IL-17A, IL-17F, IL-22, TNF-α), Th2 cytokine (IL-4), and Treg
cytokine (IL-10) expression on days 4 and 8 of treatment. Data represent the mean7S.D. (n¼5). *Po0.05, **Po0.01 as indicated.
J. Zhao et al. / European Journal of Pharmacology 772 (2016) 131–143138supernatant of cells incubated with 2 or 20 μg/ml PF contained
signiﬁcantly less IL-17 than cells incubated with no PF or 200 μg/
ml PF (Fig. 6C).
3.11. PF decreases mRNA expression of Th17 related cytokines
In mouse spleen cells incubated under Th17 polarizing condi-
tions the levels of IL-17A, IL-17F, and TNF-α mRNA were increasedand the levels of IL-22, IFN-γ, IL-4, and IL-10 mRNA were de-
creased (Po0.01; Fig. 7). Incubation with 200 μg/ml of PF de-
creased the levels of IL-17A mRNA; 20 μg/ml of PF decreased the
levels of IL-17A, IL-17F, and TNF-α mRNA, and 2 μg/ml of PF de-
creased the levels of IL-17A, and IL-17F mRNA (all Po0.01; Fig. 7).
Incubation with PF did not signiﬁcantly alter IL-22, IFN-γ, IL-4, and
IL-10 mRNA levels.
Fig. 5. Effect of PF on the phosphorylation of Th17 response related proteins. A, Representative images of p-Stat3, Stat3, p-Tyk2, Tyk2, p-Jak2, and Jak2 western blot
membranes on day 4. B, Derived values and statistical data for p-Stat3, Stat3, p-Tyk2, Tyk2, p-Jak2, and Jak2 levels on day 4. Data represent the mean7S.D., (n¼5). **Po0.01
vs. Model.
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Compared with cells cultured under neutral conditions, Th17
polarizing conditions signiﬁcantly increased the mRNA levels of the
RORγt (Po0.01): PF (200, 20, and 2 μg/ml) reduced RORγt mRNA
levels (Po0.01), and 20 μg/ml PF was the most effective (Fig. 7).
3.13. Effect of PF on the phosphorylation of Th17 differentiation re-
lated proteins in vitro
Th17 polarization elevated p-Stat3 content of splenocytes(Po0.01). In cells incubated with 2 or 20 μg/ml of PF, p-Stat3 were
reduced (Po0.01 and Po0.05, respectively; Fig. 8).4. Discussion
As the number of Th17 cells and Th17 cytokines were pre-
viously reported to be elevated in serum samples from patients
with psoriasis (Blauvelt, 2008), and were consistent with disease
severity (Johnson-Huang et al., 2010), psoriasis is thought to be
mediated by Th17 cells. Our study strongly suggests that Th17
Table 5
Effect of paeoniﬂorin on cell viability
(mean7S.D., n¼6).
Group OD (450 nm)
Neutral condition 0.62670.075a
Th17 polarizing condition 0.80670.106
PF (200 mg/ml) 0.91070.124
PF (20 mg/ml) 0.85270.082
PF (2 mg/ml) 0.78370.112
PF, paeoniﬂorin.
a Po0.05 vs. Th17 polarizing condition
group.
Fig. 6. PF reduced IL-17 secretion in vitro. A, Effect of PF on differentiation rate of
Th17 cells by ﬂow cytometry (n¼4). B, Effect of PF on intracellular IL-17 level. C,
Secretion of IL-17 was measured by culture supernatant ELISA. Data represent the
mean7S.D. (n¼4). *Po0.05, **Po0.01 as indicated.
Table 6
Effect of paeoniﬂorin on differentiation rate of Th17 cells (mean7S.D., n¼4).
Group CD4þ IL-17þ cells of CD4þ cells (%)
Neutral condition 1.4570.73%a
Th17 polarizing condition 21.4571.92%
PF (200 mg/ml) 21.470.47%
PF (20 mg/ml) 20.2472.16%
PF (2 mg/ml) 17.4274.09%
PF, paeoniﬂorin.
a Po0.01 vs. Th17 polarizing condition group.
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mouse model of psoriasis-like lesions, and that PF can modulate
the expression of Th17 cytokines in IMQ-induced psoriasis-like
skin lesions in this mouse model. Additionally, in an in vitromodel
we established that PF could directly regulate the secretion of Th17
cytokines under Th17 polarizing conditions.
Previous studies have reported that PF can enhance IL-2 pro-
duction in rat spleen lymphocytes and IL-1β release in rat peri-
toneal macrophages in a bell-shaped dose-dependent manner
(Wang et al., 2013). PF can induce spleen lymphocyte proliferation
and enable recovery of reduced lymphocyte proliferation to near
normal levels, indicating that PF has bidirectional im-
munomodulatory effects and functions in a concentration depen-
dent manner. Lymphocytes have also been reported to be the main
target cells of PF in vivo (Zhang and Dai, 2012). PF inhibits lym-
phocyte proliferation and secretion of pro-inﬂammatory cytokines,
restores the Th1/Th2 cytokine balance, playing an im-
munomodulatory role, and ameliorates the symptoms of rheu-
matoid arthritis. Wang (2010) reported that in an experimental rat
model of colitis induced by trinitrobenzene sulfonic acid, TGP can
reduce the serum levels of IL-17/IL-23-associated factor axis, and
reverse the Th17/Treg cell balance, thus easing colitis. PF regulates
serum IL-22 levels of patients with psoriasis. However, the me-
chanisms by which PF inhibits the Th17 response and related cy-
tokine secretion in animal models of psoriasis has not previously
been reported. Here, we showed that PF could ameliorate IMQ-
induced skin lesions via a Stat3-dependent mechanism involving
inhibition of Th17-mediated inﬂammatory responses.
In this study, we found that PF could inhibit psoriasis by reg-
ulating Th17 cytokine secretion. We used real-time PCR to assess
the levels of Th1/Th17/Th2/Treg cytokine mRNA in lesion tissues
and spleen cells. IMQ increased the levels of Th1/Th17/Th2/Treg
cytokine mRNA, corroborating previous ﬁndings (Zhang et al.,
2010). However, PF only ameliorated the elevated mRNA levels of
Th17 cytokines, while MTX ameliorated mRNA levels of Th17 and
Th1 cytokines. We also found that mRNA levels of Th1/Th17/Th2/
Treg cytokines were ﬁrst increased before dropping, inconsistent
with the severity of skin lesions. However, though mRNA levels
were decreased at day 8, serious skin lesions at day 8 may be the
result of subsequent changes in gene expression.
IL-23 acts on memory T cells and plays an important role in the
proliferation and maintenance of the immune response after Th17
cell differentiation (Kagami, 2011). The IL-23 receptor comprises
IL-12Rβ1 and IL-23R, which can separately combine with Tyk2 and
Jak2. IL-23 binding with IL-23R leads to the activation of the JAK
family and Stat3 phosphorylation. Activated Stat3 aggregates in
dimers and translocates to the nucleus to initiate gene transcrip-
tion (IL-17A, IL-17F, and IL-22) (Di Cesare et al., 2009). In our study,
mRNA levels of IL-23, upstream of the IL-23/IL-17 axis, were not
altered, indicating that PF does not target IL-23 expression, but
instead the downstream IL-23 receptor pathway. After mice were
treated with IMQ, phosphorylation of Tyk2 and Stat3 were in-
creased, consistent with previous reports (Kang et al., 2013). These
Fig. 7. PF decreases mRNA levels of Th17-related cytokines and RORγt in vitro. Th1 type cytokine (IFN-γ), Th17 cytokines (IL-17A, IL-17F, IL-22, and TNF-α), Th2 cytokine (IL-
4), Treg cytokine (IL-10) and RORγt mRNA levels were measued by PCR. Data represent the mean7S.D. (n¼4). *Po0.05, **Po0.01 as indicated.
J. Zhao et al. / European Journal of Pharmacology 772 (2016) 131–143 141effects could be inhibited by PE and MTX, respectively. A number
of p-Jak2 antibodies from different companies were employed, but
we did not detect p-Jak2 expression, possibly due to its low ex-
pression levels in skin lesions.IL-17 plays an important role in psoriasis. PF inhibited the ex-
pression of IL-17 in the mouse skin. Since the cells secreting IL-17
in the skin during psoriasis were mainly Th17 cells and γδT cells,
we measured the number of lymph node γδT cells in these mice.
Fig. 8. Effect of PF on the phosphorylation of Th17 response related proteins in vitro. A, Representative images of p-Stat3 and Stat3 western blot membranes of cells
incubated with PF for 72 h. B, Derived values and statistical data for p-Stat3 and Stat3 levels. Data represent the mean7S.D. (n¼4). *Po0.05 or **Po0.01 vs. Model.
J. Zhao et al. / European Journal of Pharmacology 772 (2016) 131–143142In comparison to healthy control animals, the ratio of inguinal
lymph node γδ T cells in the model group was signiﬁcantly higher,
and the ratio of γδ T cells was decreased in PF and MTX treated
animals. The inhibitory effect of PF was more substantial than that
of MTX, implying that the gamma delta lineage might be one of
the cell types targeted by PF.
Th17 cells have been implicated in the development of psor-
iasis. Here, we found that about 21% of naive CD4þ T cells from
C57BL/6 mice activated by TGF-β1, IL-6, IL-1β, anti-IL-2, anti-IL-4,
anti-IFN-γ, and IL-23 differentiated into Th17 cells, a level of dif-
ferentiation similar to that previously reported by Okamoto et al.
(2010). However, the extent of this differentiation was lower than
previously reported in other studies, probably due to the different
strains of mice employed (Zheng et al., 2007a; Janke et al., 2010).
In this experiment, mRNA levels of Th17 cytokines were sig-
niﬁcantly increased and Th1, Th2, and Treg cytokine levels were
signiﬁcantly decreased, indicating that the method used in our
study can speciﬁcally induce naive CD4þ T cells into Th17 cells,
and inhibit their differentiation into Th1, Th2, and Treg cells.
However, we also found decreased levels of IL-22 mRNA (a Th17
cytokine) with this method. Two reasons might explain this: ﬁrst,
this method cannot completely simulate the complex process of
Th17 cell differentiation in vivo, which results in induction of Th17
cells; second, IL-22 is mainly secreted by Th22, a new CD4þ T cell
type (Jia and Wu, 2014). The cytokines, and the biological function
and differentiation of this type of cells are very different from
those of Th17. Our culture method only induced Th17, and in-
hibited the differentiation of Th22. Thus, levels of IL-22 mRNA
were decreased.
RORγt is the key transcription factor that promotes the differ-
entiation of Th17 cells, and facilitates expression of genes encoding
IL-17A and IL-17F (O'Shea et al., 2009). IMQ treatment increased
the expression of RORγt in the model group after 4 days of
treatment, but this effect disappeared after 8 days of treatment. PF
signiﬁcantly reduced the mRNA expression of RORγt after 4 days
of IMQ treatment, but not after 8 days of treatment, partially
supporting the possibility that PF may regulate the Th17 cell
proportion in early skin lesions of mice with psoriasis.No tested concentration of PF altered the Th17 differentiation
rate, while 2 μg/ml of PF inhibited IL-17 expression in Th17 cells,
and 2 or 20 μg/ml of PF signiﬁcantly inhibited the secretion of IL-
17 and reduced the levels of IL-17A and IL-17F, and the Th17 cell
differentiation transcription factor RORγt mRNA. As we assessed
these measures of IL-17 mRNA or protein accumulation or secre-
tion after cells were cultured with PF for three days, we may not
have detected the effects on Th17 differentiation, which may occur
later. Additionally, these results suggest that, in these culture
conditions, PF more effectively inhibits IL-17 production and se-
cretion at 2 or 20 μg/ml compared with 200 μg/ml. This unusual
dose-response may suggest that high concentrations of PF are
detrimental to IL-17 secretion and Th17 polarization, however we
observed no detrimental effect of high doses of PF on cell viability.
The mechanism by which high doses of PF ameliorate the effects of
lower doses remains to be determined.5. Conclusions
PF can signiﬁcantly improve IMQ-induced psoriasis-like skin
lesions in mice, reducing the inﬁltration of inﬂammatory cells,
epidermal cell proliferation, and abnormal differentiation. PF can
inhibit the expression of the Th17 cytokines in mice and in vitro. PF
may act by inﬂuencing Stat3 phosphorylation and RORγt
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